查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1438239

2030 年卡波西氏肉瘤市場預測：按類型、診斷方法、治療方法、最終用戶和地區進行的全球分析

Kaposi Sarcoma Market Forecasts to 2030 - Global Analysis By Type, Diagnostic Method, Treatment Modality, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球卡波西氏肉瘤市場規模為 1.0869 億美元，預計 2030 年將達到 1.5092 億美元，預測期內年複合成長率為 4.8%。

卡波西氏肉瘤 (KS) 是一種罕見的癌症，其特徵是血管異常生長以及皮膚、黏膜和內臟器官的病變。它是由人類皰疹病毒 8 型 (HHV-8) 感染引起的，通常影響免疫系統較弱的人，例如愛滋病毒/愛滋病患者和接受免疫抑制治療的人。早期診斷和有效治療對於改善卡波西氏肉瘤患者的預後至關重要。

2022 年 3 月發表在《臨床癌症研究》上的一項研究得出結論，Pomalidomide是一種安全有效的免化療藥物，用於治療感染和未感染 HIV 患者的卡波西氏肉瘤。

愛滋病毒/愛滋病流行

HIV/愛滋病會削弱免疫系統，使人們更容易罹患卡波西氏肉瘤，這是一種與人類皰疹病毒 8 (HHV-8) 感染相關的癌症。隨著全球愛滋病毒/愛滋病盛行率的增加，卡波西氏肉瘤的發生率也隨之增加，特別是在抗逆轉錄病毒治療機會有限的地區。盛行率的上升推動了對卡波西氏肉瘤早期檢測、診斷和治療的需求，導致針對愛滋病毒/愛滋病感染者疾病管理的治療性介入、診斷工具和支持性護理服務市場不斷成長，這激勵著我。

治療的副作用

卡波西氏肉瘤的治療方法，包括化療、放射線治療和免疫療法，可能會引起嚴重的副作用。這些會導致噁心、嘔吐、脫髮和骨髓抑制，損害患者的生活品質和治療依從性。這些副作用不僅影響患者的健康，還會抑制治療順從性並需要調整劑量或停藥。

診斷的進展

診斷的進步極大地促進了早期發現和開始治療。免疫組織化學和分子生物學測試等診斷技術的改進可以更準確、更及時地識別卡波西氏肉瘤病變，從而實現早期療育並改善患者預後。此外，生物標記研究的進步將促進風險分層和個人化治療方法。此類診斷創新透過增加對診斷工具、影像設備以及與卡波西氏肉瘤診斷和監測相關的輔助服務的需求來擴大市場。

治療費用高

卡波西氏肉瘤的高治療費用主要是由於治療方法複雜且往往時間較長。這些治療方法包括化療、放射線治療、標靶治療和免疫治療，這些治療通常很昂貴且需要專門的醫學知識。此外，控制治療相關副作用的支持性護理進一步增加了整體治療成本。高昂的治療成本限制了人們獲得醫療保健的機會，尤其是在醫療資源有限的地區，並阻礙了市場的成長。

COVID-19 的影響

COVID-19 的爆發對卡波西氏肉瘤市場產生了多方面的影響。因疫情而不堪負荷的醫療保健系統轉移了非新冠相關疾病的資源，導致卡波西肉瘤的診斷和治療延誤。經濟不確定性和醫療資源的重新分配也影響了研究經費和藥物開發工作。結果，大流行加劇了卡波西肉瘤管理方面的現有挑戰，並透過擾亂患者治療途徑和研究工作阻礙了市場成長。

預計在預測期內，流行的卡波西氏肉瘤部分將是最大的

流行的卡波西肉瘤部分預計將經歷良好的成長。流行性卡波西氏肉瘤是一種在愛滋病毒/愛滋病流行期間出現的卡波西氏肉瘤，主要影響免疫力缺乏的個體。它是由人類皰疹病毒 8 型 (HHV-8) 感染引起的，其特徵是皮膚、黏膜和內臟器官出現多發性且通常廣泛的病變。愛滋病毒/愛滋病的流行，特別是在高流行地區，是導致地方性 KS 病例增加的重要原因。

預計化療領域在預測期內年複合成長率最高。

化療領域在預測期內將出現最高的年複合成長率。化療是卡波西氏肉瘤的基本治療方法，特別是進行性或侵襲性病例。最常使用的化療藥物包括微脂體細胞週期蛋白、紫杉醇和長春花生物鹼。化療的目的是縮小或穩定 KS 腫瘤、緩解症狀並提高生活品質。化療方案已被證明可以延長 KS 患者的生存期，從而加速了這群人的成長。

比最大的地區

預計亞太地區在預測期內將佔據最大的市場佔有率。印度和泰國等國家建立了強大的醫療基礎設施和研究能力。在該地區，政府、醫療機構和製藥公司之間的合作正在改善患者的治療效果。此外，加強努力擴大抗逆轉錄病毒治療的可及性並提高人們對愛滋病毒/愛滋病和相關癌症的認知，正在為亞太地區的卡波西氏肉瘤市場創造成長機會。

年複合成長率最高的地區：

由於愛滋病毒/愛滋病的高發病率、先進的醫療基礎設施以及對該疾病的認知不斷提高，預計北美在預測期內將呈現最高的年複合成長率。該地區擁有完善的製藥和生物技術產業，因此可以提供卡波西氏肉瘤的先進治療方案和臨床試驗。此外，支持性的政府政策、大量的研究經費以及提高愛滋病毒/愛滋病意識和預防的努力正在進一步推動市場成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球卡波西氏肉瘤市場：按類型

  • 經典卡波西氏肉瘤
  • 地方性卡波西氏肉瘤
  • 流行性卡波西氏肉瘤
  • 免疫抑制相關的卡波西氏肉瘤
  • 晚期卡波西氏肉瘤
  • 播散性卡波西氏肉瘤
  • 其他類型

第6章全球卡波西氏肉瘤市場：依診斷方法

  • 組織病理學
  • 免疫組織化學 (IHC)
  • 聚合酵素鏈鎖反應(PCR)
  • 切片檢查
  • 其他診斷方法

第7章全球卡波西氏肉瘤市場：依治療方法分類

  • 抗逆轉錄病毒治療（ART）
  • 化療
  • 免疫療法
  • 放射治療
  • 標靶治療
  • 其他治療方法

第8章全球卡波西氏肉瘤市場：依最終用戶分類

  • 醫院和診所
  • 癌症研究所
  • 門診手術中心
  • 家庭保健
  • 其他最終用戶

第9章全球卡波西氏肉瘤市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Abbott Laboratories
  • AbbVie Inc
  • Biogen Inc
  • Bio-Rad Laboratories
  • Cornell Engineering
  • Celgene Corporation
  • Cipla Limited
  • Eli Lilly and Company
  • Genentech Inc
  • Johnson & Johnson
  • Leo Pharma A/S
  • Merck & Co. Inc
  • Novartis International AG
  • Pfizer Inc
  • Roche Holding AG
  • Siemens Healthineers
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical
  • Thermo Fisher Scientific Inc
  • Vertex Pharmaceuticals Incorporated
Product Code: SMRC25208

According to Stratistics MRC, the Global Kaposi Sarcoma Market is accounted for $108.69 million in 2023 and is expected to reach $150.92 million by 2030 growing at a CAGR of 4.8% during the forecast period. Kaposi Sarcoma (KS) is a rare cancer characterized by abnormal growth of blood vessels and lesions on the skin, mucous membranes, and internal organs. It is caused by infection with human herpesvirus 8 (HHV-8), often affecting individuals with compromised immune systems, such as those with HIV/AIDS or undergoing immunosuppressive therapy. Early diagnosis and effective management are crucial for improving outcomes in patients with Kaposi Sarcoma.

According to the study published in Clinical Cancer Research in March 2022, the study concluded that Pomalidomide is a safe and effective chemotherapy-sparing medication for the treatment of Kaposi sarcoma in people with or without HIV.

Market Dynamics:

Driver:

Growing prevalence of HIV/AIDS

HIV/AIDS weakens the immune system, making individuals more susceptible to developing kaposi sarcoma, a cancer associated with human herpesvirus 8 (HHV-8) infections. As HIV/AIDS prevalence raises globally, particularly in regions with limited access to antiretroviral therapy, the incidence of Kaposi sarcoma increases accordingly. This heightened prevalence drives demand for early detection, diagnosis, and treatment of Kaposi sarcoma, fueling market growth for therapeutic interventions, diagnostic tools, and supportive care services aimed at managing the disease in HIV/AIDS-affected populations.

Restraint:

Side effects of therapy

The therapies for kaposi sarcoma, including chemotherapy, radiation therapy, and immunotherapy, can lead to significant side effects. They may cause nausea, vomiting, hair loss, and bone marrow suppression, compromising patients' quality of life and treatment adherence. These side effects not only impact patient well-being but also deter treatment compliance and may necessitate dose adjustments or discontinuation, thereby limiting the market growth by reducing patient acceptance and adoption of kaposi sarcoma therapies.

Opportunity:

Advancements in diagnosis

Advancements in diagnosis significantly enhance early detection and treatment initiation. Improved diagnostic techniques such as immunohistochemistry and molecular testing enable more accurate and timely identification of kaposi sarcoma lesions, leading to earlier interventions and better patient outcomes. Additionally, advances in biomarker research facilitate risk stratification and personalized therapy approaches. These diagnostic innovations expand the market by increasing the demand for diagnostic tools, imaging equipment, and ancillary services related to kaposi sarcoma diagnosis and monitoring.

Threat:

High cost of treatment

Kaposi Sarcoma's high cost of treatment is primarily attributed to the complex and often prolonged therapeutic regimens involved. These regimens may include chemotherapy, radiation therapy, and targeted or immunotherapy, which are costly to administer and often require specialized medical expertise. Additionally, supportive care to manage treatment-related side effects further adds to the overall treatment expenses. The high cost of treatment can limit access to care, particularly in regions with limited healthcare resources, thereby hampering market growth.

Covid-19 Impact

The covid-19 pandemic has had a multifaceted impact on the kaposi sarcoma market. Healthcare systems strained by the pandemic diverted resources away from non-covid-related conditions, leading to delays in Kaposi sarcoma diagnosis and treatment. Economic uncertainties and healthcare resource reallocations also affected research funding and drug development efforts. Consequently, the pandemic exacerbated existing challenges in kaposi sarcoma management and impeded market growth by disrupting patient care pathways and research endeavours.

The epidemic kaposi sarcoma segment is expected to be the largest during the forecast period

The epidemic kaposi sarcoma segment is estimated to have a lucrative growth. Epidemic Kaposi Sarcoma refers to a form of KS that emerged during the HIV/AIDS epidemic, predominantly affecting immunocompromised individuals. It is caused by human herpes virus 8 (HHV-8) infections and is characterized by the development of multiple, often widespread, lesions on the skin, mucous membranes, and internal organs. The HIV/AIDS epidemic, particularly in regions with high prevalence, significantly contributed to the rise of epidemic KS cases.

The chemotherapy segment is expected to have the highest CAGR during the forecast period

The chemotherapy segment is anticipated to witness the highest CAGR growth during the forecast period. Chemotherapy is a cornerstone treatment for Kaposi Sarcoma, particularly in advanced or aggressive cases. The most commonly used chemotherapy agents include liposomal anthracyclines, paclitaxel, and vinca alkaloids. Chemotherapy aims to shrink or stabilize KS tumors, alleviate symptoms, and improve quality of life. Chemotherapy regimens have been shown to extend survival in KS patients which is accelerating the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. Countries like India and Thailand have established strong healthcare infrastructure and research capabilities. Collaboration between governments, healthcare organizations and pharmaceutical companies in the region are improving patient outcomes. Further, increasing efforts to expand access to antiretroviral therapy, and raise awareness about HIV/AIDS and related cancers offer growth opportunities for the Kaposi Sarcoma market in Asia Pacific.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the high prevalence of HIV/AIDS, advanced healthcare infrastructure, and increasing awareness about the disease. The region's well-established pharmaceutical and biotechnology industries contribute to the availability of advanced treatment options and clinical trials for Kaposi Sarcoma. Additionally, supportive government policies, robust research funding, and initiatives promoting HIV/AIDS awareness and prevention further bolster market growth.

Key players in the market

Some of the key players profiled in the Kaposi Sarcoma Market include Abbott Laboratories, AbbVie Inc, Biogen Inc, Bio-Rad Laboratories, Cornell Engineering, Celgene Corporation, Cipla Limited, Eli Lilly and Company, Genentech Inc, Johnson & Johnson, Leo Pharma A/S, Merck & Co. Inc, Novartis International AG, Pfizer Inc, Roche Holding AG, Siemens Healthineers, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical, Thermo Fisher Scientific Inc and Vertex Pharmaceuticals Incorporated.

Key Developments:

In August 2022, Researchers at Cornell Engineering and Weill Cornell Medicine designed a portable diagnostic device that has been deployed in clinical tests in Uganda to identify cases of Kaposi sarcoma. This common yet difficult-to-detect cancer often signals the presence of HIV infection.

Types Covered:

  • Classic Kaposi Sarcoma
  • Endemic Kaposi Sarcoma
  • Epidemic Kaposi Sarcoma
  • Immunosuppression-Associated Kaposi Sarcoma
  • Latrogenic Kaposi Sarcoma
  • Disseminated Kaposi Sarcoma
  • Other Types

Diagnostic Methods Covered:

  • Histopathology
  • Immunohistochemistry (IHC)
  • Polymerase Chain Reaction (PCR)
  • Biopsy
  • Other Diagnostic Methods

Treatment Modalities Covered:

  • Antiretroviral Therapy (ART)
  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Other Therapies

End Users Covered:

  • Hospitals & Clinics
  • Cancer Research Institutions
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Kaposi Sarcoma Market, By Type

  • 5.1 Introduction
  • 5.2 Classic Kaposi Sarcoma
  • 5.3 Endemic Kaposi Sarcoma
  • 5.4 Epidemic Kaposi Sarcoma
  • 5.5 Immunosuppression-Associated Kaposi Sarcoma
  • 5.6 Latrogenic Kaposi Sarcoma
  • 5.7 Disseminated Kaposi Sarcoma
  • 5.8 Other Types

6 Global Kaposi Sarcoma Market, By Diagnostic Method

  • 6.1 Introduction
  • 6.2 Histopathology
  • 6.3 Immunohistochemistry (IHC)
  • 6.4 Polymerase Chain Reaction (PCR)
  • 6.5 Biopsy
  • 6.6 Other Diagnostic Methods

7 Global Kaposi Sarcoma Market, By Treatment Modality

  • 7.1 Introduction
  • 7.2 Antiretroviral Therapy (ART)
  • 7.3 Chemotherapy
  • 7.4 Immunotherapy
  • 7.5 Radiation Therapy
  • 7.6 Targeted Therapy
  • 7.7 Other Therapies

8 Global Kaposi Sarcoma Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Cancer Research Institutions
  • 8.4 Ambulatory Surgical Centers
  • 8.5 Home Healthcare
  • 8.6 Other End Users

9 Global Kaposi Sarcoma Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 AbbVie Inc
  • 11.3 Biogen Inc
  • 11.4 Bio-Rad Laboratories
  • 11.5 Cornell Engineering
  • 11.6 Celgene Corporation
  • 11.7 Cipla Limited
  • 11.8 Eli Lilly and Company
  • 11.9 Genentech Inc
  • 11.10 Johnson & Johnson
  • 11.11 Leo Pharma A/S
  • 11.12 Merck & Co. Inc
  • 11.13 Novartis International AG
  • 11.14 Pfizer Inc
  • 11.15 Roche Holding AG
  • 11.16 Siemens Healthineers
  • 11.17 Takeda Pharmaceutical Company Limited
  • 11.18 Teva Pharmaceutical
  • 11.19 Thermo Fisher Scientific Inc
  • 11.20 Vertex Pharmaceuticals Incorporated

List of Tables

  • Table 1 Global Kaposi Sarcoma Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Kaposi Sarcoma Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Kaposi Sarcoma Market Outlook, By Classic Kaposi Sarcoma (2021-2030) ($MN)
  • Table 4 Global Kaposi Sarcoma Market Outlook, By Endemic Kaposi Sarcoma (2021-2030) ($MN)
  • Table 5 Global Kaposi Sarcoma Market Outlook, By Epidemic Kaposi Sarcoma (2021-2030) ($MN)
  • Table 6 Global Kaposi Sarcoma Market Outlook, By Immunosuppression-Associated Kaposi Sarcoma (2021-2030) ($MN)
  • Table 7 Global Kaposi Sarcoma Market Outlook, By Latrogenic Kaposi Sarcoma (2021-2030) ($MN)
  • Table 8 Global Kaposi Sarcoma Market Outlook, By Disseminated Kaposi Sarcoma (2021-2030) ($MN)
  • Table 9 Global Kaposi Sarcoma Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 10 Global Kaposi Sarcoma Market Outlook, By Diagnostic Method (2021-2030) ($MN)
  • Table 11 Global Kaposi Sarcoma Market Outlook, By Histopathology (2021-2030) ($MN)
  • Table 12 Global Kaposi Sarcoma Market Outlook, By Immunohistochemistry (IHC) (2021-2030) ($MN)
  • Table 13 Global Kaposi Sarcoma Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 14 Global Kaposi Sarcoma Market Outlook, By Biopsy (2021-2030) ($MN)
  • Table 15 Global Kaposi Sarcoma Market Outlook, By Other Diagnostic Methods (2021-2030) ($MN)
  • Table 16 Global Kaposi Sarcoma Market Outlook, By Treatment Modality (2021-2030) ($MN)
  • Table 17 Global Kaposi Sarcoma Market Outlook, By Antiretroviral Therapy (ART) (2021-2030) ($MN)
  • Table 18 Global Kaposi Sarcoma Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 19 Global Kaposi Sarcoma Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 20 Global Kaposi Sarcoma Market Outlook, By Radiation Therapy (2021-2030) ($MN)
  • Table 21 Global Kaposi Sarcoma Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 22 Global Kaposi Sarcoma Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 23 Global Kaposi Sarcoma Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Kaposi Sarcoma Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 25 Global Kaposi Sarcoma Market Outlook, By Cancer Research Institutions (2021-2030) ($MN)
  • Table 26 Global Kaposi Sarcoma Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 27 Global Kaposi Sarcoma Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 28 Global Kaposi Sarcoma Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.